CN116940662A - 不含防腐剂的隐形眼镜处理溶液 - Google Patents
不含防腐剂的隐形眼镜处理溶液 Download PDFInfo
- Publication number
- CN116940662A CN116940662A CN202280019442.3A CN202280019442A CN116940662A CN 116940662 A CN116940662 A CN 116940662A CN 202280019442 A CN202280019442 A CN 202280019442A CN 116940662 A CN116940662 A CN 116940662A
- Authority
- CN
- China
- Prior art keywords
- contact lens
- preservative
- treatment solution
- free contact
- lens treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 52
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 52
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 52
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 239000000872 buffer Substances 0.000 claims abstract description 31
- 239000004386 Erythritol Substances 0.000 claims abstract description 28
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 28
- 229940009714 erythritol Drugs 0.000 claims abstract description 28
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 28
- 235000019414 erythritol Nutrition 0.000 claims abstract description 28
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 23
- 239000001103 potassium chloride Substances 0.000 claims abstract description 21
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 21
- 239000011780 sodium chloride Substances 0.000 claims abstract description 14
- 239000000243 solution Substances 0.000 claims description 210
- 238000000034 method Methods 0.000 claims description 32
- 229920001983 poloxamer Polymers 0.000 claims description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
- 239000000314 lubricant Substances 0.000 claims description 18
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 17
- 229960000502 poloxamer Drugs 0.000 claims description 16
- 229920001987 poloxamine Polymers 0.000 claims description 14
- -1 pH adjusters Substances 0.000 claims description 13
- 229940123208 Biguanide Drugs 0.000 claims description 12
- 239000002280 amphoteric surfactant Substances 0.000 claims description 10
- 239000004599 antimicrobial Substances 0.000 claims description 10
- 229910021538 borax Inorganic materials 0.000 claims description 10
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 10
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 9
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 9
- 239000004327 boric acid Substances 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 9
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000003889 eye drop Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003974 emollient agent Substances 0.000 claims description 5
- 239000002738 chelating agent Substances 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 4
- WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical compound [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 claims description 4
- 239000000607 artificial tear Substances 0.000 claims description 3
- 230000001050 lubricating effect Effects 0.000 claims description 3
- 235000010338 boric acid Nutrition 0.000 claims 3
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 description 20
- 239000000203 mixture Substances 0.000 description 18
- 238000004659 sterilization and disinfection Methods 0.000 description 18
- 230000001954 sterilising effect Effects 0.000 description 17
- 229920001400 block copolymer Polymers 0.000 description 12
- 239000000178 monomer Substances 0.000 description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 10
- 229920001222 biopolymer Polymers 0.000 description 10
- 238000004140 cleaning Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000000017 hydrogel Substances 0.000 description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 150000004283 biguanides Chemical class 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000249 desinfective effect Effects 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 229920000570 polyether Polymers 0.000 description 6
- 229920001451 polypropylene glycol Polymers 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 4
- 229960003237 betaine Drugs 0.000 description 4
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- PEQJBOMPGWYIRO-UHFFFAOYSA-N n-ethyl-3,4-dimethoxyaniline Chemical compound CCNC1=CC=C(OC)C(OC)=C1 PEQJBOMPGWYIRO-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 3
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 3
- 229950010221 alexidine Drugs 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 229940117986 sulfobetaine Drugs 0.000 description 3
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 150000008054 sulfonate salts Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- BRJJFBHTDVWTCJ-UHFFFAOYSA-N 1-[n'-[6-[[amino-[[n'-(2-ethylhexyl)carbamimidoyl]amino]methylidene]amino]hexyl]carbamimidoyl]-2-(2-ethylhexyl)guanidine;dihydrochloride Chemical compound Cl.Cl.CCCCC(CC)CN=C(N)NC(N)=NCCCCCCN=C(N)NC(N)=NCC(CC)CCCC BRJJFBHTDVWTCJ-UHFFFAOYSA-N 0.000 description 1
- QRIMLDXJAPZHJE-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CO QRIMLDXJAPZHJE-UHFFFAOYSA-N 0.000 description 1
- LTHJXDSHSVNJKG-UHFFFAOYSA-N 2-[2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOCCOC(=O)C(C)=C LTHJXDSHSVNJKG-UHFFFAOYSA-N 0.000 description 1
- RXGSAYBOEDPICZ-UHFFFAOYSA-N 2-[6-[[amino-(diaminomethylideneamino)methylidene]amino]hexyl]-1-(diaminomethylidene)guanidine Chemical compound NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)N RXGSAYBOEDPICZ-UHFFFAOYSA-N 0.000 description 1
- RXMNFWAHGZIZJV-UHFFFAOYSA-N 2-carboxyoxyethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOC(O)=O RXMNFWAHGZIZJV-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- ZQYUHRVUJCLGRX-UHFFFAOYSA-N NCC(=O)NCC(O)=O.NCC(=O)NCC(O)=O Chemical compound NCC(=O)NCC(O)=O.NCC(=O)NCC(O)=O ZQYUHRVUJCLGRX-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 241000120020 Tela Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FZQSLXQPHPOTHG-UHFFFAOYSA-N [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 Chemical compound [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 FZQSLXQPHPOTHG-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000882 contact lens solution Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920013746 hydrophilic polyethylene oxide Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000012569 microbial contaminant Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- JVUYWILPYBCNNG-UHFFFAOYSA-N potassium;oxido(oxo)borane Chemical compound [K+].[O-]B=O JVUYWILPYBCNNG-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
- A01N33/02—Amines; Quaternary ammonium compounds
- A01N33/12—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/52—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing groups, e.g. carboxylic acid amidines
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/10—Halogens or compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
- A61L12/141—Biguanides, e.g. chlorhexidine
- A61L12/142—Polymeric biguanides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
- A61L12/143—Quaternary ammonium compounds
- A61L12/145—Polymeric quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/66—Non-ionic compounds
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/66—Non-ionic compounds
- C11D1/72—Ethers of polyoxyalkylene glycols
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/66—Non-ionic compounds
- C11D1/722—Ethers of polyoxyalkylene glycols having mixed oxyalkylene groups; Polyalkoxylated fatty alcohols or polyalkoxylated alkylaryl alcohols with mixed oxyalkylele groups
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/66—Non-ionic compounds
- C11D1/835—Mixtures of non-ionic with cationic compounds
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0047—Other compounding ingredients characterised by their effect pH regulated compositions
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/02—Inorganic compounds ; Elemental compounds
- C11D3/04—Water-soluble compounds
- C11D3/046—Salts
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/20—Organic compounds containing oxygen
- C11D3/2003—Alcohols; Phenols
- C11D3/2065—Polyhydric alcohols
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/20—Organic compounds containing oxygen
- C11D3/22—Carbohydrates or derivatives thereof
- C11D3/222—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/20—Organic compounds containing oxygen
- C11D3/22—Carbohydrates or derivatives thereof
- C11D3/222—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin
- C11D3/227—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin with nitrogen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/26—Organic compounds containing nitrogen
- C11D3/30—Amines; Substituted amines ; Quaternized amines
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2101/00—Chemical composition of materials used in disinfecting, sterilising or deodorising
- A61L2101/02—Inorganic materials
- A61L2101/06—Inorganic materials containing halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2101/00—Chemical composition of materials used in disinfecting, sterilising or deodorising
- A61L2101/32—Organic compounds
- A61L2101/34—Hydroxy compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2101/00—Chemical composition of materials used in disinfecting, sterilising or deodorising
- A61L2101/32—Organic compounds
- A61L2101/46—Macromolecular compounds
- A61L2101/50—Polysaccharides or derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Ophthalmology & Optometry (AREA)
- Environmental Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Eyeglasses (AREA)
- Medicinal Preparation (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Detergent Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
一种不含防腐剂的隐形眼镜处理溶液包含(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.005wt.%至约2wt.%的透明质酸或其盐;(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的赤藓糖醇;(c)一种或多种非离子表面活性剂;(d)氯化钠、氯化钾或其任何组合;以及(e)一种或多种缓冲液。
Description
优先权声明
本申请要求于2021年3月10日提交的题为“眼用溶液(Ophthalmic Solutions)”的美国临时专利申请序列号63/159,097的优先权,所述美国临时专利申请的内容通过引用整体并入本文。
背景技术
在正常使用期间,隐形眼镜会被各种各样的可能降低镜片的性能的化合物染污或污染。例如,隐形眼镜将被泪液中存在并粘附到镜片表面的生物材料,如蛋白质或脂质染污。而且,通过操作隐形眼镜,皮脂(皮肤油)、化妆品或其它材料可能会染污隐形眼镜。这些生物和外部污染物可能影响视力和患者的舒适度。因此,有利的是从镜片表面去除任何碎屑,以便与镜片护理溶液一起继续舒适使用。
发明内容
根据一说明性实施例,一种不含防腐剂的隐形眼镜处理溶液包括(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.005wt.%至约2wt.%的透明质酸或其盐;(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的赤藓糖醇;(c)一种或多种非离子表面活性剂;(d)氯化钠和氯化钾中的一种或多种;以及(e)一种或多种缓冲液。
根据另一说明性实施例,一种重新润湿隐形眼镜的方法,所述方法包括在佩戴在眼睛上时向隐形眼镜施用不含防腐剂的隐形眼镜处理溶液,其中所述不含防腐剂的隐形眼镜重新润湿溶液包括(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.005wt.%至约2wt.%的透明质酸或其盐;(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的赤藓糖醇;(c)一种或多种非离子表面活性剂;(d)氯化钠和氯化钾中的一种或多种;以及(e)一种或多种缓冲液。
根据又另一说明性实施例,一种可用作人工泪液或用于当隐形眼镜在眼睛中时重新润湿或润滑所述隐形眼镜的系统,所述系统包括液滴分配器,所述液滴分配器能够容纳约1ml至约30ml的不含防腐剂的隐形眼镜处理溶液,所述不含防腐剂的隐形眼镜处理溶液包括(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.005wt.%至约2wt.%的透明质酸或其盐;(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的赤藓糖醇;(c)一种或多种非离子表面活性剂;(d)氯化钠、氯化钾或其任何组合;以及(e)一种或多种缓冲液。
根据仍又另一说明性实施例,一种不含防腐剂的隐形眼镜处理溶液的用途,其用于重新润湿隐形眼镜,所述不含防腐剂的隐形眼镜处理溶液包括(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.005wt.%至约2wt.%的透明质酸或其盐;(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的赤藓糖醇;(c)一种或多种非离子表面活性剂;(d)氯化钠、氯化钾或其任何组合;以及(e)一种或多种缓冲液。
具体实施方式
本文所描述的说明性实施例涉及可用作滴眼液的不含防腐剂的隐形眼镜处理溶液,例如,用于处理佩戴在眼睛中的隐形眼镜的表面的重新润湿滴液。
许多生物聚合物对常见的灭菌程序敏感,例如热灭菌。热灭菌通常可能导致生物聚合物的物理化学特性发生显著变化,从而使所得无菌生物聚合物不适合其预期用途。
目前应用于医疗材料的灭菌方法包含例如热处理、高压蒸汽灭菌(例如,高压灭菌器灭菌)、环氧乙烷气体(EOG)灭菌、超临界二氧化碳灭菌和辐射灭菌。可用的灭菌方法通常关于要灭菌的特定生物聚合物的稳健性进行评估。例如,仅在生物聚合物能够承受高温和高压的范围内,高压蒸气灭菌才能用于生物聚合物。然而,包含透明质酸在内的极少数生物聚合物能够承受如此高温和高压。
透明质酸是一种非免疫原性物质,并且由于其粘弹特性和亲水特性,透明质酸多年来一直被用作眼睛玻璃体或关节液的替代品,或眼科手术中的支持介质。在关节液中,透明质酸溶液用作润滑剂,以为细胞提供保护环境,并且因此,其用于治疗发炎的膝关节。消费者使用包含透明质酸的产品需要制造商对消费品进行灭菌,并且如果用作开放式多剂量调配物,则必须采取另外的步骤来保存调配物产品。
已知透明质酸是一种对热灭菌过程相对敏感的生物聚合物。已知透明质酸的热灭菌会加速透明质酸的水解或氧化,由此导致生物聚合物的平均分子量显著且通常有害地降低。对于许多药物应用,调配物中相对低分子量形式的透明质酸是不期望的。通常,低分子量形式的透明质酸不能提供高分子量形式的透明质酸所期望的流变特性。为了补偿透明质酸在上述热灭菌方法中的分解,可以从具有比期望的分子量更高的分子量的透明质酸开始。然而,这种调节导致工艺效率低下,这是因为透明质酸的产物产率随着生物聚合物的平均分子量的增加而降低。
本文所描述的说明性实施例通过调配透明质酸或其盐的改善的无菌不含防腐剂的隐形眼镜处理溶液克服了这一问题和其它问题,所述溶液可以在透明质酸或其盐没有实质降解的情况下进行灭菌。具体地,通过在本文所公开的不含防腐剂的隐形眼镜处理溶液中将透明质酸或其盐与赤藓糖醇组合,当经受灭菌条件,如高压灭菌时,透明质酸随时间推移的分子量损失在统计学上显著好于在不存在赤藓糖醇的情况下含有透明质酸或其盐的不含防腐剂的隐形眼镜处理溶液。因此,本文所公开的其中当经历灭菌条件时透明质酸或其盐的分子量损失得到改善的不含防腐剂的隐形眼镜处理溶液将有利地表现出更少的pH问题、更少的功效问题、改善的粘度和更少的氧化和热降解,由此导致更高的稳定性和更长的保质期。另外,本文所公开的不含防腐剂的隐形眼镜处理溶液还有利地对用于制备溶液的水中所含的任何铁表现出更高的耐受性,这是通过将透明质酸或其盐与赤藓糖醇组合来实现的,并且由此提供更稳健的溶液。
在一个或多个非限制性说明性实施例中,一种不含防腐剂的隐形眼镜处理溶液包括(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.005wt.%至约2wt.%的透明质酸或其盐;(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的赤藓糖醇;(c)一种或多种非离子表面活性剂;(d)氯化钠和氯化钾中的一种或多种;以及(e)一种或多种缓冲液。
本文所公开的不含防腐剂的隐形眼镜处理溶液将包含基于所述不含防腐剂的隐形眼镜处理溶液的总重量,至少约0.005wt.%至约2wt.%的透明质酸或其盐。透明质酸是一种众所周知的天然水溶性生物可降解聚合物,由两种交替连接的糖,D-葡萄糖醛酸和N-乙酰葡糖胺构成,通过交替的β-(1,4)和β-(1,3)糖苷键连接。透明质酸与其它糖胺聚糖不同,因为其与蛋白质和磺酰基没有共价连接。透明质酸在动物体内普遍存在,其中发现在软结缔组织中浓度最高。透明质酸对于身体的机械和运输目的两者都发挥着重要作用,例如,其赋予关节弹性和脊椎动物椎间盘刚性,并且也是眼睛玻璃体的重要组成。
透明质酸聚合物在相对低的溶质浓度的水溶液中具有亲水性和高粘性。其通常以钠盐、透明质酸钠的形式天然存在。制备可商购获得的透明质酸和其盐的方法是众所周知的。透明质酸可以从以下购买:例如,生化学工业株式会社公司(Seikagaku Company);清液生物技术有限公司(Clear Solutions Biotech,Inc.);法玛西亚有限公司(PharmaciaInc.);西格玛有限公司(Sigma Inc.);HTL生物技术公司(HTL Biotechnology);Contipro公司;华熙生物科技公司(Bloomage Biotechnology Corporation)以及许多其它供应商。透明质酸具有由下式表示的结构的重复单元:
因此,透明质酸中的重复单元可以如下:
通常,透明质酸或其盐,如透明质酸钠和透明质酸钾的二糖单元可以为约2个至约1,500,000个。在一个实施例中,透明质酸或其盐的重均分子量可以在约10,000至约3,000,000道尔顿(Da)的范围内,其中下限为约10,000、约20,000、约30,000、约40,000、约50,000、约60,000、约70,000、约80,000、约90,000、约100,000、约200,000、约300,000、约400,000、约500,000或约600,000Da,并且上限为约200,000、约300,000、约400,000、约500,000、约600,000、约700,000、约800,000、约900,000、约1,000,000或约至多2,800,000Da,其中任何下限可以与任何上限组合。
在一说明性实施例中,基于不含防腐剂的隐形眼镜处理溶液的总重量,透明质酸或其盐以范围为约0.005wt.%至约2wt.%的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。在另一说明性实施例中,基于不含防腐剂的隐形眼镜处理溶液的总重量,透明质酸或其盐以范围为约0.01wt.%至约0.2wt.%的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。
本文所公开的不含防腐剂的隐形眼镜处理溶液进一步含有赤藓糖醇。在一说明性实施例中,基于不含防腐剂的隐形眼镜处理溶液的总重量,赤藓糖醇以范围为约0.01wt.%至约1wt.%的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。在另一说明性实施例中,基于不含防腐剂的隐形眼镜处理溶液的总重量,赤藓糖醇以范围为约0.05wt.%至约0.5wt.%的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。在另一说明性实施例中,基于不含防腐剂的隐形眼镜处理溶液的总重量,赤藓糖醇以范围为约0.08wt.%至约0.4wt.%的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。
本文所公开的不含防腐剂的隐形眼镜处理溶液进一步含有一种或多种非离子表面活性剂。在说明性实施例中,合适的一种或多种非离子表面活性剂包含例如一种或多种末端官能化的表面活性剂。合适的非离子表面活性剂举例来说包含一种或多种聚醚。有用的末端官能化的聚醚包括一个或多个链或聚合物组分,其具有一个或多个(-O-R-)重复单元,其中R是具有2个至约6个碳原子的亚烷基或亚芳基。聚醚可以衍生自由不同比率组分的环氧乙烷(EO)和环氧丙烷(PO)形成的嵌段共聚物。此类聚醚和其相应组分区段可以包含不同的连接的疏水性和亲水性化学官能团部分和区段。
可以末端官能化的合适的聚醚的一个非限制性代表性实例是泊洛沙姆嵌段共聚物(poloxamer block copolymer)。一类特定的泊洛沙姆嵌段共聚物是可以商标普朗尼克(Pluronic)(密歇根州怀恩多特的BASF怀恩多特公司)获得的那些。泊洛沙姆包含普朗尼克类和反向普朗尼克类。普朗尼克类是一系列ABA嵌段共聚物,由聚(环氧乙烷)-聚(环氧丙烷)-聚(环氧乙烷)嵌段构成,如式(I)通常所表示的:
HO(C2H4O)a(C3H6O)b(C2H4O)aH (I),
其中a独立地是至少1并且b是至少1。
反向普朗尼克类是一系列BAB嵌段共聚物,分别由聚(环氧丙烷)-聚(环氧乙烷)-聚(环氧丙烷)嵌段构成,如式(II)通常所表示的:
HO(C3H6O)b(C2H4O)a(C3H6O)bH (II),
其中a是至少1并且b独立地是至少1。聚(环氧乙烷)PEO嵌段是亲水性的,而聚(环氧丙烷)PPO嵌段本质上是疏水性的。每个系列中的泊洛沙姆具有不同比率的PEO和PPO,这最终决定了材料的亲水-亲脂性平衡(HLB),即,变化的HLB值基于a和b的变化值,a表示存在于分子中的亲水性聚(环氧乙烷)单元(PEO)的数量,并且b表示存在于分子中的疏水性聚(环氧丙烷)单元(PPO)的数量。
泊洛沙姆和反向泊洛沙姆具有可以末端官能化的末端羟基。末端官能化的泊洛沙姆并且如下文所讨论的一个实例是泊洛沙姆二甲基丙烯酸酯(例如,F127二甲基丙烯酸酯),如美国专利申请公开第2003/0044468号和美国专利第9,309,357号中所公开的。其它实例包含聚乙二醇和聚丙二醇的缩水甘油基封端的共聚物,如美国专利第6,517,933号中所公开的。
合适的聚醚的另一个非限制性代表性实例是泊洛沙明嵌段共聚物(poloxamineblock copolymer)。虽然泊洛沙姆和反向泊洛沙姆被认为是双官能分子(基于末端羟基),但泊洛沙明是四官能形式,即分子是终止于伯羟基并通过中心二胺连接的四官能嵌段共聚物。一类特定的泊洛沙明嵌段共聚物是可以商标特窗酸(Tetronic)(BASF)获得的那些。泊洛沙明包含特窗酸和反向特窗酸。泊洛沙明具有下式(III)的一般结构:
其中a独立地是至少1并且b独立地是至少1。
泊洛沙姆和/或泊洛沙明可以被官能化以在分子的末端处提供期望的反应性。官能度可以变化,并且基于官能化的含PEO和PPO的嵌段共聚物的预期用途来确定。如本文所使用的,术语嵌段共聚物应理解为意指在其聚合物主链中具有两个或更多个嵌段的泊洛沙姆和/或泊洛沙明。
在一说明性实施例中,本文所公开的不含防腐剂的隐形眼镜处理溶液含有泊洛沙姆和泊洛沙明中的一种或多种作为所述一种或多种非离子表面活性剂。在一说明性实施例中,本文所公开的不含防腐剂的隐形眼镜处理溶液含有分子量为约7,500至约27,000的泊洛沙明,如泊洛沙明1107(特窗酸1107),其中至少约40重量%的加合物是聚(氧乙烯)。
在一说明性实施例中,基于不含防腐剂的隐形眼镜处理溶液的总重量,所述一种或多种非离子表面活性剂以范围为约0.05wt.%至约5wt.%的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。在另一说明性实施例中,基于不含防腐剂的隐形眼镜处理溶液的总重量,所述一种或多种非离子表面活性剂以范围为约0.1wt.%至约2wt.%的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。在另一说明性实施例中,基于不含防腐剂的隐形眼镜处理溶液的总重量,所述一种或多种非离子表面活性剂以范围为约0.1wt.%至约1.5wt.%的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。
本文所公开的不含防腐剂的隐形眼镜处理溶液进一步含有有效量的一种或多种张力调节组分。合适的张力调节组分包含例如隐形眼镜护理产品中常规使用的组分,如各种无机盐。在一说明性实施例中,合适的张力调节组分包含氯化钠、氯化钾和其组合。所述一种或多种张力调节组分的量是有效地为不含防腐剂的溶液提供期望张力程度的量。
在一说明性实施例中,基于不含防腐剂的隐形眼镜处理溶液的总重量,所述一种或多种张力调节组分以范围为约0.01wt.%至约5wt.%的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。在另一说明性实施例中,基于不含防腐剂的隐形眼镜处理溶液的总重量,所述一种或多种张力调节组分以范围为约0.01wt.%至约1wt.%的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。在另一说明性实施例中,基于不含防腐剂的隐形眼镜处理溶液的总重量,所述一种或多种张力调节组分以范围为约0.01wt.%至约0.08wt.%的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。
本文所公开的不含防腐剂的隐形眼镜处理溶液进一步含有一种或多种缓冲液。术语“缓冲液”和“缓冲液系统”被理解为意指单独或与至少一种其它化合物组合在溶液中提供缓冲系统的化合物,所述缓冲系统表现出缓冲能力,即在其中原始pH变化相对较小或没有变化的一定范围内中和酸或碱(base/alkali)的能力。术语“缓冲能力”被理解为意指当添加到一升(标准单位)缓冲溶液中时,将pH值改变一个单位所需的强酸或强碱(或分别为氢或氢氧根离子)的毫摩尔(mM)。缓冲容量将取决于缓冲组分的类型和浓度。缓冲容量是在约6至约8、或约7.4至约8.4的起始pH下测量的。
合适的缓冲液包含例如硼酸和其盐,如硼酸钠或硼酸钾。硼酸盐缓冲液还包含缓冲化合物,如例如在溶液中产生硼酸或其盐的四硼酸钾或偏硼酸钾。已知硼酸盐缓冲液增强某些聚合双胍的功效。例如,美国专利第4,758,595号描述了一种含有聚(六亚甲基双胍),也称为PHMB或PAPB的隐形眼镜溶液,如果与硼酸盐缓冲液组合,其可以表现出增强的功效。其它合适的缓冲液包含双甘肽(双甘氨肽)和柠檬酸钠。
在一说明性实施例中,所述一种或多种缓冲液以范围为约0.1%至约10%(w/w)的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。在另一说明性实施例中,所述一种或多种缓冲液以范围为约0.5%至约5%(w/w)的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。在另一说明性实施例中,所述一种或多种缓冲液以范围为约0.75%至约2%(w/w)的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。
在说明性实施例中,本文所公开的不含防腐剂的隐形眼镜处理溶液进一步含有有效量的一种或多种润滑剂组分。合适的润滑剂组分包含例如眼用产品中常规使用的润滑剂组分。在一说明性实施例中,合适的润滑剂组分包含非离子二醇,如甘油和丙二醇和其组合。
在一说明性实施例中,基于不含防腐剂的隐形眼镜处理溶液的总重量,所述一种或多种润滑剂组分以范围为约0.01wt.%至约5wt.%的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。在另一说明性实施例中,基于不含防腐剂的隐形眼镜处理溶液的总重量,所述一种或多种润滑剂组分以范围为约0.01wt.%至约1wt.%的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。
在非限制性说明性实施例中,本文所公开的不含防腐剂的隐形眼镜处理溶液不含任何防腐剂。例如,已知在眼用组合物中用作防腐剂的各种抗微生物剂。因此,在非限制性说明性实施例中,本文所公开的不含防腐剂的隐形眼镜处理溶液不含抗微生物剂。在另外的说明性实施例中,本文所公开的不含防腐剂的隐形眼镜处理溶液不含双胍或其盐或其游离碱;季铵化合物或其盐或者其游离碱;萜烯或其衍生物;支化的甘油单烷基醚;支化的甘油单烷基胺;支化的甘油单烷基硫;脂肪酸单酯,其中脂肪酸单酯包括具有六个至十四个碳原子的脂肪族脂肪酸部分和脂肪族羟基部分,以及酰氨基胺化合物。
在又另外的说明性实施例中,本文所公开的不含防腐剂的隐形眼镜处理溶液不含非聚合物双胍、聚合物双胍、其盐、其游离碱等和其混合物和/或季铵化合物或其盐或其游离碱。非聚合物双胍的代表性实例包含双(双胍),如阿来西定、氯己定、阿来西定盐,例如阿来西定HCl、氯己定盐、阿来西定游离碱等和其混合物。阿来西定和氯己定的盐可以是有机的或无机的,并且通常是消毒硝酸盐、乙酸盐、磷酸盐、硫酸盐、卤化物等。聚合物双胍的代表性实例包含聚合物六亚甲基双胍(PHMB)(可从特拉华州威尔明顿的泽尼卡商购获得)、其聚合物和水溶性盐。在一个实施例中,用于本文的水溶性聚合物双胍的数均分子量可以是至少约1,000或数均分子量是约1,000至约50,000。合适的游离碱的水溶性盐包含例如盐酸盐、硼酸盐、乙酸盐、葡萄糖酸盐、磺酸盐、酒石酸盐和柠檬酸盐。
PHMB或聚六甲基双胍最好描述为包括至少三种且优选地至少六种双胍聚合物的聚合物双胍组合物,我们称之为PHMB-A、PHMB-CG和PHMB-CGA,其一般化学结构描绘如下。
季铵化合物的代表性实例包含聚[(二甲基亚氨基)-2-丁烯-1,4-二酰氯]和[4-三(2-羟乙基)铵]-2-丁烯-w-[三(2-羟乙基)铵]-二氯化物(化学注册号75345-27-6),其通常可作为聚季铵盐-1以商品名M(伊利诺伊州诺思菲尔德的斯泰潘公司(StepanCompany,Northfield,Ill))获得。季铵化合物在本领域中通常被称为“聚季铵盐”,并且在名称后面用特定的数字来标识,如聚季铵盐-1、聚季铵盐-10、聚季铵盐-42等。
除上述组分外,本文所公开的不含防腐剂的隐形眼镜处理溶液可以进一步含有一种或多种两性表面活性剂、舒适剂、pH调节剂、螯合剂、粘度调节剂、缓和剂等。两性表面活性剂是具有酸性和碱性特性两者的表面活性化合物。用于本文的两性表面活性剂包含一类称为甜菜碱的化合物。甜菜碱的特征在于完全季铵化的氮原子,并且在碱性溶液中不表现出阴离子特性,这意味着甜菜碱在接近中性的pH下仅以两性离子的形式存在。在一个实施例中,合适的两性表面活性剂由式(IV)的结构表示:
其中R1是任选地被羟基或-(CH2)n-NHC(O)R取代的C8至C30烷基,其中R是任选地被羟基取代的C8至C30烷基,并且n是2、3或4;R2和R3各自独立地是氢或C1至C4烷基;R4是任选地被羟基取代的C2至C8亚烷基;并且Y是CO2 -或SO3 -。
甜菜碱的特征在于完全季铵化的氮。在烷基甜菜碱中,季铵化氮的烷基之一是具有八个到三十个碳原子的烷基链。一类甜菜碱是磺基甜菜碱或羟基磺基甜菜碱,其中烷基甜菜碱的羧基被磺酸盐替代。在羟基磺基甜菜碱中,羟基位于从季铵化氮延伸到磺酸盐的亚烷基碳之一上。在烷基氨基甜菜碱中,酰胺基团被插入作为疏水性C8至C30烷基链与季铵化氮之间的连接。
在一说明性实施例中,式IV的两性表面活性剂可以是式(V)的磺基甜菜碱:
其中R1是C8到C30烷基;R2和R3各自独立地是C1至C4烷基;并且R4是C2至C8亚烷基。某些通式V的磺基甜菜碱比其它磺基甜菜碱更优选。例如,可从Calbiochem公司获得的93-10是式V的磺基甜菜碱,其中R1是具有十(10)个碳的直链饱和烷基,R2和R3各自是甲基,并且R4 i是-CH2CH2CH2-(三个碳,(3))。可用于隐形眼镜处理组合物中的其它磺基甜菜碱包含例如对应的/>3-08(即,R1是具有八个碳的直链饱和烷基)、/>3-12(即,R1是具有十二个碳的直链饱和烷基)、/>3-14(即,R1是具有十四个碳的直链饱和烷基)和/>3-16(即,R1是具有十六个碳的直链饱和烷基)。在一个实施例中,磺基甜菜碱具有式V,并且R1是C8至C16烷基;并且R2和R3是甲基。
在另一个实施例中,式IV的两性表面活性剂是式(VI)的羟基磺基甜菜碱:
其中R1是被至少一个羟基取代的C8至C30烷基;R2和R3各自独立地是C1至C4烷基;并且R4是被至少一个羟基取代的C2至C8亚烷基。
在另一个实施例中,两性表面活性剂是式(VII)的烷基氨基甜菜碱:
其中R1是C8至C30烷基,并且m和n独立地选自2、3、4或5;R2和R3各自独立地是任选地被羟基取代的C1到C4烷基;R4是任选地被羟基取代的C2至C8亚烷基;并且Y是CO2 -或SO3 -。在一个说明性实施例中,烷基氨基甜菜碱的代表性实例包含烷基氨基丙基甜菜碱,例如椰油氨基丙基二甲基甜菜碱和月桂酰氨基丙基二甲基甜菜碱。
本文所公开的不含防腐剂的隐形眼镜处理溶液可以进一步含有一种或多种舒适组分或缓冲组分。舒适组分可以增强和/或延长表面活性剂组分的清洁和润湿活性和/或调节镜片表面,使其更亲水(不太亲脂性)和/或对眼睛充当缓和剂。舒适组分被认为在放置镜片期间缓冲对眼睛表面的影响,并且还用于减轻眼睛刺激。
合适的舒适组分包含例如水溶性天然树胶、纤维素衍生聚合物等。有用的天然树胶包含瓜尔胶、黄芪胶等。有用的纤维素衍生的舒适组分包含纤维素衍生的聚合物,如羟丙基纤维素、羟丙基甲基纤维素、羧甲基纤维素、甲基纤维素、羟乙基纤维素等。一些非纤维素舒适组分包含丙二醇或甘油。在一说明性实施例中,舒适组分可以以范围为约0.01%至约1%(w/w)的量存在于本文所公开的不含防腐剂的隐形眼镜处理溶液中。
在一实施例中,据信维持水合角膜表面的舒适剂是聚乙烯吡咯烷酮(PVP)。PVP是线性均聚物或基本上包括至少90%衍生自1-乙烯基-2-吡咯烷酮单体的重复单元的线性均聚体,单体组合物的其余部分可以包含中性单体,例如乙烯基或丙烯酸盐。PVP的其它同义词包含聚维酮(povidone/polyvidone)、1-乙烯基-2-吡咯烷酮和1-乙烯基-2-吡咯烷酮(CAS注册号9003-39-8)。PVP的重均分子量可以为约10,000至约250,000或约30,000至约100,000。此类材料由多家公司销售,包含ISP技术有限公司,商标为K-29/32;BASF公司,商标为/>例如/>K-30或K-90。还优选地使用药物级PVP。
本文所公开的不含防腐剂的隐形眼镜处理溶液还可以包含一种或多种螯合组分,以帮助在日常使用后从镜片表面去除脂质和蛋白质沉积物。通常,不含防腐剂的隐形眼镜处理溶液将包含相对少量,例如约0.005%至约0.05%(w/w)的乙二胺四乙酸(EDTA)或其对应金属盐,如二钠盐Na2EDTA。
在一说明性实施例中,本文所公开的不含防腐剂的隐形眼镜处理溶液的渗透压的范围可以在至少约200mOsmol/kg到至多约400mOsmol/kg,例如至少约250或至少约300或约350,各自至多约400mOsmol/kg。不含防腐剂的隐形眼镜处理溶液是基本上等渗的或高渗的(例如,轻微高渗的),并且是眼用可接受的。
在非限制性说明性实施例中,本文所公开的不含防腐剂的隐形眼镜处理溶液包含旨在用于在眼睛中应用或用于在与眼睛接触之后或之前处理隐形眼镜的溶液。因此,不含防腐剂的隐形眼镜处理溶液可以包含用于直接放置在眼睛中的组合物,包含滴眼液溶液,如用于处理干眼症和在佩戴时重新润湿隐形眼镜的滴眼液,以及也符合多用途溶液资格的滴眼液溶液。
与本文所公开的不含防腐剂的隐形眼镜处理溶液接触的隐形眼镜的类型不是关键的,并且可以设想任何隐形眼镜。此类镜片的代表性实例包含但不限于软性隐形眼镜,例如软性水凝胶镜片;软性非水凝胶镜片等,硬性隐形眼镜,例如,硬性可透气镜片材料等,刚性可透气(RGP)镜片、人工晶状体、重叠镜片等。如本领域技术人员所理解的,如果镜片可以折回其自身而不破裂,则认为所述镜片是“软性的”。本文可以使用任何已知的产生隐形眼镜的材料。例如,不含防腐剂的隐形眼镜处理溶液可以用于(1)由通过丙烯酸酯聚合,如聚(甲基丙烯酸甲酯)(PMMA)制备的材料形成的硬性镜片;(2)由硅酮丙烯酸酯和氟硅酮甲基丙烯酸脂形成的RGP镜片;以及(3)由水凝胶聚合材料,如硅酮水凝胶制成的软性水凝胶隐形眼镜,其中水凝胶被定义为含有处于平衡状态的水的交联聚合物系统。
通常,水凝胶表现出优异的生物相容性特性,即通过不在活组织中产生毒性、损伤性或免疫应答而具有生物或生化相容性特性。代表性常规水凝胶隐形眼镜材料是通过使包括至少一种亲水性单体的单体混合物聚合而制备的,所述亲水性单体如(甲基)丙烯酸、甲基丙烯酸2-羟基乙酯(HEMA)、甲基丙烯酸甘油酯、N,N-二甲基丙烯酰胺和N-乙烯基吡咯烷酮(NVP)。在硅酮水凝胶的情况下,制备共聚物的单体混合物除亲水性单体外,进一步包含含硅酮的单体。通常,单体混合物还将包含交联单体,如乙二醇二甲基丙烯酸酯、四甘醇二甲基丙烯酸酯和碳酸甲基丙烯酰氧酯乙酯。可替代地,含硅酮的单体或亲水性单体可以充当交联剂。
本文所公开的不含防腐剂的隐形眼镜处理溶液在生理上是相容的。具体地,不含防腐剂的隐形眼镜处理溶液与隐形眼镜一起使用必须是“眼用安全的”,这意味着用不含防腐剂的溶液处理的隐形眼镜通常适于且安全地直接放置在眼睛上,也就是说,溶液对于通过用不含防腐剂的隐形眼镜处理溶液重新润湿的隐形眼镜与眼睛的日常接触是安全且舒适的。眼用安全溶液具有与眼睛相容的张力和pH,并且包括根据ISO(国际标准组织)标准和美国FDA规定的非细胞毒性的材料和其量。不含防腐剂的隐形眼镜处理溶液应是无菌的,因为在释放之前,必须在统计学上证明此类产品中不存在微生物污染物,达到此类产品所需的程度。
本文所公开的不含防腐剂的隐形眼镜处理溶液可以成液滴的形式,并且可用作隐形眼镜的含此类材料的清洁、消毒或调节组合物的组分。在一个实施例中,本文所公开的不含防腐剂的隐形眼镜处理溶液可以被调配成“多用途溶液”。多用途溶液可用于清洁、消毒、储存和冲洗镜片,尤其是软性隐形眼镜。术语“多用途溶液”也不排除这样的可能性,不每天使用定期清洁剂或用于进一步去除蛋白质的补充清洁剂,例如通常每周使用的酶清洁剂。术语“清洁”意指溶液中含有一种或多种浓度足以松动和去除松散保持在隐形眼镜的表面上的镜片沉积物和其它污染物的试剂,其可以与数字操纵(例如,用溶液手动摩擦镜片)或与搅拌与镜片接触的溶液,例如机械清洁助剂的辅助装置结合使用。
传统上,市场上的多用途溶液需要一种涉及用多用途溶液机械摩擦镜片的方案,以提供所需的消毒和清洁。对于不符合化学消毒溶液资格的化学消毒系统,政府监管机构(如FDA或美国食品和药物管理局(FDA))要求采用这种方案。在一个实施例中,有可能调配清洁和消毒产品,其一方面能够在不存在摩擦方案的情况下提供改善的清洁和消毒,并且另一方面足够温和以用作润湿剂,例如,用作滴眼液。例如,符合化学消毒溶液资格的产品必须符合FDA为隐形眼镜护理产品制定的杀菌性能标准(1997年5月1日),所述标准不涉及镜片的摩擦。在一说明性实施例中,本文所公开的不含防腐剂的隐形眼镜处理溶液被调配成符合FDA或ISO独立程序针对隐形眼镜消毒产品的要求。类似地,本文所公开的组合物可以被调配成在不使用摩擦方案的情况下提供增强的清洁。与传统的多用途消毒和清洁产品相比,此类调配物可以确保更高的患者依从性和更大的普遍吸引力。多用途溶液的粘度可以小于约75cps、或约1cps至约50cps或约1cps至约25cps,或者所述多用途溶液在总组合物中可以具有至少约95容重%的水。
本文所公开的不含防腐剂的隐形眼镜处理溶液和/或组合物的pH可以保持在约4.0至约9.0、或约5.0至约8.0、或约6.0至约8.0或约6.5至约7.8的pH范围内。在一个实施例中,pH值至多大于或等于约7。
在非限制性说明性实施例中,提供了一种重新润湿隐形眼镜的方法。例如,一种方法包括在佩戴在眼睛上时向隐形眼镜施用如本文所公开的不含防腐剂的隐形眼镜处理溶液,如不含防腐剂的隐形眼镜处理溶液,其中所述不含防腐剂的隐形眼镜处理溶液包括(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.005wt.%至约2wt.%的透明质酸或其盐;(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的赤藓糖醇;(c)一种或多种非离子表面活性剂;(d)氯化钠、氯化钾或其任何组合;以及(e)一种或多种缓冲液。如本领域技术人员将容易理解的,不含防腐剂的隐形眼镜处理溶液可以在必要时佩戴在眼睛上时周期性地应用于隐形眼镜。不含防腐剂的隐形眼镜处理溶液可以含有如上文所讨论的任何相应量的组分。
在非限制性说明性实施例中,可用作人工泪液或用于在隐形眼镜在眼睛中重新润湿或润滑所述隐形眼镜的系统包括液滴分配器,所述液滴分配器能够容纳约1ml至约30ml本文所公开的不含防腐剂的隐形眼镜处理溶液。
提供以下实例以使本领域技术人员能够实践本文所描述的说明性实施例,并且以下实例仅是说明性的。实例不应被认为限制如权利要求中所限定的所说明的实施例的范围。
实例1
不含防腐剂的隐形眼镜处理溶液的制备适于重新润湿佩戴在眼睛上的隐形眼镜。量是基于溶液的总重量的wt.%或ppm,其中纯化水用于q.s至100wt.%。
第一溶液通过添加硼酸(0.6wt.%)、硼酸钠(0.25wt.%)、氯化钾(0.21wt.%)、赤藓糖醇(0.3wt.%)、甘油(0.5wt.%)和泊洛沙明1107(0.2wt.%)来制备。然后将溶液样品加热至40℃或75℃。
在冷却至室温之后,添加透明质酸钠(0.15wt.%)并搅拌过夜。
比较实例1
类似于实例1制备溶液,但缺少赤藓糖醇。
透明质酸分子量损失研究
向实例1和比较实例1的不含防腐剂的隐形眼镜处理溶液的样品中添加5ppm过氧化氢,并且然后在40℃和75℃下高压灭菌20小时。对于在40℃和75℃下温育的两种溶液,与比较实例1的不含防腐剂的隐形眼镜处理溶液相比,实例1的不含防腐剂的隐形眼镜处理溶液显示出统计学上显著更低的透明质酸的分子量损失量。
为了简洁起见,在单个实施例的上下文中描述的本文所公开的不含防腐剂的隐形眼镜处理溶液的各种特征也可以单独地或以任何合适的子组合提供。说明性实施例具体涵盖实施例的所有组合,并且在本文中公开,就好像每个和每个组合被单独和明确地公开一样。另外,描述这些变量的实施例中列出的所有子组合也被明确地涵盖在本发明组合物中,并且在本文中公开,如同每个此类子组合在本文中单独和明确地公开一样。
将理解,可对本文中所公开的实施例进行各种修改。因此,以上说明不应该被解释为限制性的,但是仅作为优选实施例的例示。例如,上文所描述的并且实施为用于操作本文所描述的实施例的最佳模式的功能仅用于说明目的。在不脱离本发明的范围和精神的情况下,本领域技术人员可以实施其它布置和方法。此外,所属领域技术人员将构想出在所附特征和优点的范围和精神内的其它修改。
Claims (49)
1.一种不含防腐剂的隐形眼镜处理溶液,其包括:
(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.005wt.%至约2wt.%的透明质酸或其盐;
(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的赤藓糖醇;
(c)一种或多种非离子表面活性剂;
(d)氯化钠、氯化钾或其任何组合;以及
(e)一种或多种缓冲液。
2.根据权利要求1所述的不含防腐剂的隐形眼镜处理溶液,其中所述透明质酸或其盐的重均分子量在约100,000至约3,000,000道尔顿(Da)的范围内。
3.根据权利要求1或2所述的不含防腐剂的隐形眼镜处理溶液,其包括:
(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约0.2wt.%的透明质酸或其盐;以及
(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.05wt.%至约0.5wt.%的赤藓糖醇。
4.根据权利要求1至3所述的不含防腐剂的隐形眼镜处理溶液,其中所述一种或多种非离子表面活性剂包括泊洛沙姆(poloxamer)和泊洛沙明(poloxamine)中的一种或多种。
5.根据权利要求1至4所述的不含防腐剂的隐形眼镜处理溶液,其中所述一种或多种缓冲液包括硼酸钠和硼酸钾中的一种或多种。
6.根据权利要求1至5所述的不含防腐剂的隐形眼镜处理溶液,其包括:
基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.05wt.%至约5wt.%的所述一种或多种非离子表面活性剂;
基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约5wt.%的氯化钠、氯化钾或其任何组合;以及
约0.1%至约10%(w/w)的所述一种或多种缓冲液。
7.根据权利要求1所述的不含防腐剂的隐形眼镜处理溶液,其包括透明质酸钠、赤藓糖醇、泊洛沙明、氯化钾、硼酸和硼酸钠。
8.根据权利要求7所述的不含防腐剂的隐形眼镜处理溶液,其包括:
(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约0.2wt.%的透明质酸钠;
(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.05wt.%至约0.5wt.%的赤藓糖醇;
(c)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.1wt.%至约2wt.%的泊洛沙明;
(d)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的氯化钾;以及
(e)约0.1%至约10%(w/w)的硼酸和硼酸钠。
9.根据权利要求1至8所述的不含防腐剂的隐形眼镜处理溶液,其进一步包括一种或多种润滑剂。
10.根据权利要求1至8所述的不含防腐剂的隐形眼镜处理溶液,其进一步包括基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约5wt.%的一种或多种润滑剂。
11.根据权利要求1至8所述的不含防腐剂的隐形眼镜处理溶液,其进一步包括基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的一种或多种润滑剂。
12.根据权利要求9至11所述的不含防腐剂的隐形眼镜处理溶液,其中所述一种或多种润滑剂包括甘油。
13.根据权利要求1至12所述的不含防腐剂的隐形眼镜处理溶液,其进一步包括以下中的一种或多种:两性表面活性剂、舒适剂、pH调节剂、螯合剂、粘度调节剂和缓和剂。
14.根据权利要求1至13所述的不含防腐剂的隐形眼镜处理溶液,其呈滴眼液的形式。
15.根据权利要求1至14所述的不含防腐剂的隐形眼镜处理溶液,其不含抗微生物剂。
16.根据权利要求1至14所述的不含防腐剂的隐形眼镜处理溶液,其不含双胍抗微生物剂和季铵抗微生物剂中的一种或多种。
17.一种重新润湿隐形眼镜的方法,所述方法包括在佩戴在眼睛上时向隐形眼镜施用不含防腐剂的隐形眼镜处理溶液,其中所述不含防腐剂的隐形眼镜处理溶液包括(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.005wt.%至约2wt.%的透明质酸或其盐;(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的赤藓糖醇;(c)一种或多种非离子表面活性剂;(d)氯化钠、氯化钾或其任何组合;以及(e)一种或多种缓冲液。
18.根据权利要求17所述的方法,其中所述透明质酸或其盐的重均分子量在约100,000至约3,000,000道尔顿(Da)的范围内。
19.根据权利要求17或18所述的方法,其中所述不含防腐剂的隐形眼镜处理溶液包括:
(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约0.2wt.%的透明质酸或其盐;以及
(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.05wt.%至约0.5wt.%的赤藓糖醇。
20.根据权利要求17至19所述的方法,其中所述一种或多种非离子表面活性剂包括泊洛沙姆和泊洛沙明中的一种或多种。
21.根据权利要求17至20所述的方法,其中所述一种或多种缓冲液包括硼酸钠和硼酸钾中的一种或多种。
22.根据权利要求17至21所述的方法,其中所述不含防腐剂的隐形眼镜处理溶液包括:
基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.05wt.%至约5wt.%的所述一种或多种非离子表面活性剂;
基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约5wt.%的氯化钠、氯化钾或其任何组合;以及
约0.1%至约10%(w/w)的所述一种或多种缓冲液。
23.根据权利要求17所述的方法,其中所述不含防腐剂的隐形眼镜处理溶液包括透明质酸钠、赤藓糖醇、泊洛沙明、氯化钾、硼酸和硼酸钠。
24.根据权利要求23所述的方法,其中所述不含防腐剂的隐形眼镜处理溶液包括:
(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约0.2wt.%的透明质酸钠;
(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.05wt.%至约0.5wt.%的赤藓糖醇;
(c)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.1wt.%至约2wt.%的泊洛沙明;
(d)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的氯化钾;以及
(e)约0.1%至约10%(w/w)的硼酸和硼酸钠。
25.根据权利要求17至24所述的方法,其中所述不含防腐剂的隐形眼镜处理溶液进一步包括一种或多种润滑剂。
26.根据权利要求17至24所述的方法,其中所述不含防腐剂的隐形眼镜处理溶液进一步包括基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约5wt.%的一种或多种润滑剂。
27.根据权利要求17至24所述的方法,其中所述不含防腐剂的隐形眼镜处理溶液进一步包括基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的一种或多种润滑剂。
28.根据权利要求25至27所述的方法,其中所述一种或多种润滑剂包括甘油。
29.根据权利要求17至28所述的方法,其中所述不含防腐剂的隐形眼镜处理溶液进一步包括以下中的一种或多种:两性表面活性剂、舒适剂、pH调节剂、螯合剂、粘度调节剂和缓和剂。
30.根据权利要求17至29所述的方法,其中所述不含防腐剂的隐形眼镜处理溶液呈滴眼液的形式。
31.根据权利要求17至30所述的方法,其中所述不含防腐剂的隐形眼镜处理溶液不含抗微生物剂。
32.根据权利要求17至30所述的方法,其中所述不含防腐剂的隐形眼镜处理溶液不含双胍抗微生物剂和季铵抗微生物剂中的一种或多种。
33.一种能用作人工泪液或用于当隐形眼镜在眼睛中时重新润湿或润滑所述隐形眼镜的系统,所述系统包括液滴分配器,所述液滴分配器能够容纳约1ml至约30ml的不含防腐剂的隐形眼镜处理溶液,所述不含防腐剂的隐形眼镜处理溶液包括(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.005wt.%至约2wt.%的透明质酸或其盐;(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的赤藓糖醇;(c)一种或多种非离子表面活性剂;(d)氯化钠、氯化钾或其任何组合;以及(e)一种或多种缓冲液。
34.根据权利要求33所述的系统,其中所述透明质酸或其盐的重均分子量在约100,000至约3,000,000道尔顿(Da)的范围内。
35.根据权利要求33或34所述的系统,其中所述不含防腐剂的隐形眼镜处理溶液包括:
(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约0.2wt.%的透明质酸或其盐;以及
(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.05wt.%至约0.5wt.%的赤藓糖醇。
36.根据权利要求33至35所述的系统,其中所述一种或多种非离子表面活性剂包括泊洛沙姆和泊洛沙明中的一种或多种。
37.根据权利要求33至36所述的系统,其中所述一种或多种缓冲液包括硼酸钠和硼酸钾中的一种或多种。
38.根据权利要求33至37所述的系统,其中所述不含防腐剂的隐形眼镜处理溶液包括:
基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.05wt.%至约5wt.%的所述一种或多种非离子表面活性剂;
基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约5wt.%的氯化钠、氯化钾或其任何组合;以及
约0.1%至约10%(w/w)的所述一种或多种缓冲液。
39.根据权利要求33所述的系统,其中所述不含防腐剂的隐形眼镜处理溶液包括透明质酸钠、赤藓糖醇、泊洛沙明、氯化钾、硼酸和硼酸钠。
40.根据权利要求39所述的系统,其中所述不含防腐剂的隐形眼镜处理溶液包括:
(a)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约0.2wt.%的透明质酸钠;
(b)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.05wt.%至约0.5wt.%的赤藓糖醇;
(c)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.1wt.%至约2wt.%的泊洛沙明;
(d)基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的氯化钾;以及
(e)约0.1%至约10%(w/w)的硼酸和硼酸钠。
41.根据权利要求33至40所述的系统,其中所述不含防腐剂的隐形眼镜处理溶液进一步包括一种或多种润滑剂。
42.根据权利要求33至40所述的系统,其中所述不含防腐剂的隐形眼镜处理溶液进一步包括基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约5wt.%的一种或多种润滑剂。
43.根据权利要求33至40所述的系统,其中所述不含防腐剂的隐形眼镜处理溶液进一步包括基于所述不含防腐剂的隐形眼镜处理溶液的总重量,约0.01wt.%至约1wt.%的一种或多种润滑剂。
44.根据权利要求41至43所述的系统,其中所述一种或多种润滑剂包括甘油。
45.根据权利要求33至44所述的系统,其中所述不含防腐剂的隐形眼镜处理溶液进一步包括以下中的一种或多种:两性表面活性剂、舒适剂、pH调节剂、螯合剂、粘度调节剂和缓和剂。
46.根据权利要求33至45所述的系统,其中所述不含防腐剂的隐形眼镜处理溶液呈滴眼液的形式。
47.根据权利要求33至46所述的系统,其中所述不含防腐剂的隐形眼镜处理溶液不含抗微生物剂。
48.根据权利要求33至46所述的系统,其中所述不含防腐剂的隐形眼镜处理溶液不含双胍抗微生物剂和季铵抗微生物剂中的一种或多种。
49.一种根据权利要求1至16所述的不含防腐剂的隐形眼镜处理溶液的用途,其用于重新润湿隐形眼镜。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163159097P | 2021-03-10 | 2021-03-10 | |
US63/159,097 | 2021-03-10 | ||
PCT/EP2022/056144 WO2022189552A1 (en) | 2021-03-10 | 2022-03-10 | Preservative-free contact lens treating solution |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116940662A true CN116940662A (zh) | 2023-10-24 |
Family
ID=80999252
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280019442.3A Pending CN116940662A (zh) | 2021-03-10 | 2022-03-10 | 不含防腐剂的隐形眼镜处理溶液 |
CN202280019437.2A Pending CN116963720A (zh) | 2021-03-10 | 2022-03-10 | 眼用溶液 |
CN202280018795.1A Pending CN116981761A (zh) | 2021-03-10 | 2022-03-10 | 隐形眼镜处理溶液 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280019437.2A Pending CN116963720A (zh) | 2021-03-10 | 2022-03-10 | 眼用溶液 |
CN202280018795.1A Pending CN116981761A (zh) | 2021-03-10 | 2022-03-10 | 隐形眼镜处理溶液 |
Country Status (10)
Country | Link |
---|---|
US (4) | US20220290073A1 (zh) |
EP (3) | EP4304555A1 (zh) |
JP (3) | JP2024509214A (zh) |
KR (3) | KR20230156748A (zh) |
CN (3) | CN116940662A (zh) |
AU (3) | AU2022233951A1 (zh) |
BR (3) | BR112023017376A2 (zh) |
CA (3) | CA3212309A1 (zh) |
MX (3) | MX2023010372A (zh) |
WO (3) | WO2022189552A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116024050A (zh) * | 2022-12-14 | 2023-04-28 | 江苏视准医疗器械有限公司 | 一种角膜接触镜保存液组合物及其制备方法 |
US20240218291A1 (en) * | 2022-12-22 | 2024-07-04 | Bausch + Lomb Ireland Limited | Contact lens treating solution |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4758595A (en) | 1984-12-11 | 1988-07-19 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
US5573726A (en) | 1993-09-22 | 1996-11-12 | Alcon Laboratories, Inc. | Use of amidoamines in ophthalmic compositions |
KR20000036193A (ko) * | 1996-09-20 | 2000-06-26 | 스티븐 에이. 헬렁 | 콘택트 렌즈를 재습윤시키고 안구 건조감을 경감시키는 방법 및조성물 |
US6517933B1 (en) | 2000-01-18 | 2003-02-11 | Nano-Tex, Llc | Hybrid polymer materials |
JP2004527291A (ja) | 2001-03-20 | 2004-09-09 | アイトゲノッシスシェ・テヒニッシュ・ホーホシューレ・ツューリヒ | 生体材料として使用するための熱感受性ポリマーの二段階加工 |
US8569367B2 (en) * | 2004-11-16 | 2013-10-29 | Allergan, Inc. | Ophthalmic compositions and methods for treating eyes |
US8759321B2 (en) | 2007-06-13 | 2014-06-24 | Bausch & Lomb Incorporated | Ophthalmic composition with hyaluronic acid and polymeric biguanide |
US8119112B2 (en) | 2008-01-31 | 2012-02-21 | Bausch & Lomb Incorporated | Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid |
US9096819B2 (en) | 2008-01-31 | 2015-08-04 | Bausch & Lomb Incorporated | Ophthalmic compositions with an amphoteric surfactant and an anionic biopolymer |
HUE044555T2 (hu) * | 2013-02-01 | 2019-11-28 | Allergan Inc | Nátrium-hialuronátot és karboximetil-cellulózt tartalmazó mûkönny |
US9309357B2 (en) | 2013-06-18 | 2016-04-12 | Bausch & Lomb Incorporated | Synthesis of free radical polymerizable ethylenically unsaturated poloxamers and poloxamines |
US20180098937A1 (en) | 2016-10-12 | 2018-04-12 | Ps Therapies Ltd | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
US20230235247A1 (en) * | 2016-10-12 | 2023-07-27 | Ps Therapy, Inc. | Contact lens compositions and methods of use thereof |
CN112312791B (zh) * | 2018-06-27 | 2023-05-26 | 鲍希与洛姆伯股份有限公司 | 包装溶液 |
-
2022
- 2022-03-10 CN CN202280019442.3A patent/CN116940662A/zh active Pending
- 2022-03-10 WO PCT/EP2022/056144 patent/WO2022189552A1/en active Application Filing
- 2022-03-10 JP JP2023553726A patent/JP2024509214A/ja active Pending
- 2022-03-10 AU AU2022233951A patent/AU2022233951A1/en active Pending
- 2022-03-10 EP EP22713905.2A patent/EP4304555A1/en active Pending
- 2022-03-10 WO PCT/EP2022/056158 patent/WO2022189557A1/en active Application Filing
- 2022-03-10 WO PCT/EP2022/056132 patent/WO2022189548A1/en active Application Filing
- 2022-03-10 CA CA3212309A patent/CA3212309A1/en active Pending
- 2022-03-10 AU AU2022235192A patent/AU2022235192A1/en active Pending
- 2022-03-10 BR BR112023017376A patent/BR112023017376A2/pt unknown
- 2022-03-10 CN CN202280019437.2A patent/CN116963720A/zh active Pending
- 2022-03-10 EP EP22713903.7A patent/EP4305143A1/en active Pending
- 2022-03-10 CA CA3212305A patent/CA3212305A1/en active Pending
- 2022-03-10 JP JP2023555213A patent/JP2024508986A/ja active Pending
- 2022-03-10 MX MX2023010372A patent/MX2023010372A/es unknown
- 2022-03-10 CA CA3212315A patent/CA3212315A1/en active Pending
- 2022-03-10 MX MX2023010373A patent/MX2023010373A/es unknown
- 2022-03-10 JP JP2023554392A patent/JP2024508961A/ja active Pending
- 2022-03-10 KR KR1020237034629A patent/KR20230156748A/ko unknown
- 2022-03-10 KR KR1020237034628A patent/KR20230156932A/ko unknown
- 2022-03-10 EP EP22713899.7A patent/EP4305142A1/en active Pending
- 2022-03-10 US US17/691,263 patent/US20220290073A1/en active Pending
- 2022-03-10 US US17/691,265 patent/US11944638B2/en active Active
- 2022-03-10 MX MX2023010375A patent/MX2023010375A/es unknown
- 2022-03-10 KR KR1020237034627A patent/KR20230156747A/ko unknown
- 2022-03-10 CN CN202280018795.1A patent/CN116981761A/zh active Pending
- 2022-03-10 BR BR112023017375A patent/BR112023017375A2/pt unknown
- 2022-03-10 BR BR112023017725A patent/BR112023017725A2/pt unknown
- 2022-03-10 US US17/691,260 patent/US20220290072A1/en active Pending
- 2022-03-10 AU AU2022231886A patent/AU2022231886A1/en active Pending
-
2024
- 2024-02-22 US US18/584,219 patent/US20240189342A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112023017375A2 (pt) | 2023-10-03 |
KR20230156747A (ko) | 2023-11-14 |
WO2022189548A1 (en) | 2022-09-15 |
CN116963720A (zh) | 2023-10-27 |
EP4305143A1 (en) | 2024-01-17 |
MX2023010373A (es) | 2023-09-12 |
JP2024508961A (ja) | 2024-02-28 |
WO2022189557A1 (en) | 2022-09-15 |
EP4304555A1 (en) | 2024-01-17 |
AU2022231886A1 (en) | 2023-09-14 |
MX2023010375A (es) | 2023-09-12 |
AU2022235192A1 (en) | 2023-09-14 |
AU2022233951A1 (en) | 2023-09-14 |
KR20230156932A (ko) | 2023-11-15 |
KR20230156748A (ko) | 2023-11-14 |
CA3212315A1 (en) | 2022-09-15 |
JP2024508986A (ja) | 2024-02-28 |
EP4305142A1 (en) | 2024-01-17 |
MX2023010372A (es) | 2023-09-12 |
BR112023017376A2 (pt) | 2023-10-03 |
US20220290072A1 (en) | 2022-09-15 |
BR112023017725A2 (pt) | 2023-10-03 |
WO2022189552A1 (en) | 2022-09-15 |
US20220290073A1 (en) | 2022-09-15 |
US20240189342A1 (en) | 2024-06-13 |
CN116981761A (zh) | 2023-10-31 |
US11944638B2 (en) | 2024-04-02 |
CA3212305A1 (en) | 2022-09-15 |
JP2024509214A (ja) | 2024-02-29 |
CA3212309A1 (en) | 2022-09-15 |
US20220288107A1 (en) | 2022-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101487218B1 (ko) | 말단 아민 함량이 낮은 비구아나이드 조성물 | |
EP2171025B1 (en) | Ophthalmic composition with hyaluronic acid | |
US9096819B2 (en) | Ophthalmic compositions with an amphoteric surfactant and an anionic biopolymer | |
EP2178571B1 (en) | Ophthalmic compositions comprising a carboxyl-modified fructan or a salt thereof | |
WO2009097028A1 (en) | Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid | |
CN116940662A (zh) | 不含防腐剂的隐形眼镜处理溶液 | |
US9125405B2 (en) | Contact lens solution with a tertiary amine oxide | |
EP2348850A2 (en) | Lens care solutions comprising alkyldimonium hydroxypropyl alkylglucosides | |
EP2903655B1 (en) | Minimizing biological lipid deposits on contact lenses | |
EP2664665B1 (en) | Ophthalmic compositions with biguanide and PEG-glycerol esters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |